tbuckley/cabot-search huggingface dataset:
Surgical Anatomy
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TennCare
Authors: G. P. Dewberry
Journal: JAMA (1996)

<h3>In Reply.</h3> —We take pleasure in responding to comments elicited by our article. Drs Himmelstein and Woolhandler report a lower rate of insurance coverage in Tennessee than we did. Our data were derived from state reports. A University of Tennessee survey in August 1994 also reported an uninsured rate of 5.9%, a fall from 9% in 1993 before TennCare. TennCare enrollment currently includes more than 400 000 previously uninsured citizens.<sup>1</sup>Thus, TennCare did have a positive effect on coverage. Differences in quantitative values from those of other surveys are likely the result of methodologic differences, not the more pejorative reason of "sleight of hand." Dr Gore raises several issues that reflect differences of position more than inaccuracies. Whether a 60% response rate of initial enrollment was high or low is clearly one of perspective. We agree with the recent report by the Henry J. Kaiser Family Foundation and the
Acute peripheral arterial occlusion
Authors: E. A. Edwards
Journal: JAMA (1973)

Sudden cessation of major arterial flow in the extremities may be caused by physical obstruction of the arterial lumen or by reduction in effective flow when vascular volume or perfusion pressure is critically decreased or when the resistance in small arteries or venules is markedly increased (Table 1). Arterial obstruction is probably most frequently encountered in patients who have had an arterial puncture or cannulation for left atrioventricular catheterization, arteriography, or physiological monitoring. In a collective study of 12,367 patients who had cardiac catheterization, Braunwald and Swan<sup>1</sup>noted an arterial complication rate of only 0.3%. This low incidence of complications probably represents only truly disastrous events and contrasts sharply with the experience of others. In catheter procedures, the loss of the peripheral pulse per se, irrespective of symptoms of ischemia, has been encountered in about 30% of the cases.<sup>2-5</sup>Intra-arterial injection of hypertonic or otherwise irritating material, including concentrated
Screening for diastolic heart failure among elderly patients: Experience from a randomised, multicentre, clinical trial comparing perindopril and placebo: The PEP-CHF study, UK centres Jackie Taylor, John G. F. Cleland, Michael Lye, Christopher Gray, Tumpa Banerjee, Eve Shannon, Nick Wisniacki, John Baxter, Emma Owen, Anne Spensley, Anita Dunn. University of Hull, Kingston upon Hull, United Kingdom, Royal Infirmary, Glasgow, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
The Status of Oral Surgery
Authors: Kurt H. Thoma
Journal: New England Journal of Medicine (1957)

The Federal ServicesAll branches of the armed forces have assigned oral surgery to the Dental Corps. In the Army, Navy, Public Health Service and Veterans Administration hospitals, oral surgery is firmly anchored to the dental department. In these institutions there is an excellent relation between the members of the two professions. One of the officers, chief of a dental service, writes as follows regarding a recommendation by the Council of Hospital Dental Service of the American Dental Association, protesting the recommendation that oral surgery be placed under general surgery:Being a dentist, member of the A.D.A., and diplomate of . . .
How much for one unit of DLQI improvement? A cost-effectiveness analysis of biologics in psoriasis
Authors: John O'gorman, Beena Koshy, Carol Reed, Meena Subramanyam, Daniel Pearce, Andrew Nelson, Alan Fleischer, Rajesh Balkrishnan, Steven Feldman, How Psoriasis, Affects Self-Esteem, Alexa Kimball, Seth Stevens, Angelika Jahreis, Gerald Krueger
Journal: Journal of the American Academy of Dermatology (2005)
Defusing inflammasomes
Authors: Andrew Sandstrom, Russell E. Vance
Journal: The Journal of Experimental Medicine (2018)

In this issue of JEM, Boucher et al. (https://doi.org/10.1084/jem.20172222) report isolation of active caspase-1 from macrophages after inflammasome activation. Surprisingly, they find that caspase-1 is quickly inactivated upon autoproteolytic processing.
Error in Results
Authors: Clifford Jack
Journal: JAMA Neurology (2020)

Shelagh B. Coutts, MD; Francois Moreau, MD; Negar Asdaghi, MD; Jean-Martin Boulanger, MD; Marie-Christine Camden, MD; Bruce C. V. Campbell, PhD; Andrew M. Demchuk, MD; Thalia S. Field, MD; Mayank Goyal, MD; Martin Krause, MD; Jennifer Mandzia, MD; Bijoy K. Menon, MD; Robert Mikulik, MD; Andrew M. Penn, MD; Richard H. Swartz, MD; Michael D. Hill, MD; for the Diagnosis of Uncertain-Origin Benign Transient Neurological Symptoms (DOUBT) Study Group
Statistical Issues in Carcinogenic Risk Assessment
Authors: Howard E. Rockette
Journal: Environmental Health Perspectives (1991)

Considerable progresshas been made on the deveopment of a variety of analytic methods to aid in the carcinogenic risk associated with eposure to both 0cct landeiementlant AlU the development ofthese methods has been accompanied by consideration ofmany issues, there are many areas where additional effort could be diected ffthese analical nethods are to pibde the most appot pin eisk.These is hwlide n ofcombiung multiple studies to obtai anover riske the a softheati d model, methodsof s ftion among competing modes, an at of the effect of different measures ofexposure on the estimated dose-response relationship, and development of surveillance methodology.These issues are discussed, and productive areas of future reseach are indicated.
Skin markings in malignant melanoma
Authors: E. E. Bondi
Journal: JAMA (1983)

Photographic analysis of the skin markings in 92 malignant melanomas (66 superficial spreading, seven nodular, 12 acral lentiginous, and seven lentigo maligna melanomas) was undertaken. Skin markings are uniformly eradicated in areas of vertical growth phase disease and sometimes in areas of regression. Not only were skin markings always preserved in areas of radial growth phase disease, but they were sometimes accentuated. For all types of melanoma, loss of skin markings is a poor diagnostic criterion because it is a late sign associated with invasion of the dermis and thus a deteriorating prognosis. (<i>JAMA</i>1983;250:503-505)
Abstract 2612: Derived Fibrinogen Versus Brain Natriuretic Peptide and C-Reactive Protein as a Predictor of Events After Myocardial Infarction
Authors: Terry R Ketch, Samuel J Turner, Matthew T Sacrinty, Kevin C Lingle, Robert J Applegate, Michael A Kutcher, David C Sane
Journal: Circulation (2007)

Multiple biomarkers have been studied to assess risk for future coronary events. Fibrinogen is involved in platelet aggregation, thrombus formation, and is a marker of inflammation. Furthermore, prothrombin time-derived fibrinogen levels are widely available with routine coagulation assays. We retrospectively evaluated admission derived fibrinogen, BNP and CRP levels as well as baseline clinical and procedural characteristics of 475 consecutive patients admitted with acute myocardial infarction who subsequently underwent stent placement. Major adverse cardiac event (MACE) outcomes data were collected to two years after index admission. Higher quartiles of admission fibrinogen levels were associated with increased hazard of death from any cause (log-rank p-value &lt;0.001), non-fatal myocardial infarction (log-rank p-value &lt;0.001), and any MACE (log-rank p-value = 0.004) at two years. In a Cox proportional hazards multivariate model including the covariates age (10 years), heart failure class, smoking status, diabetes, hypertension, cerebrovascular disease, history of renal failure, previous PCI and/or CABG, multivessel coronary disease, BNP and CRP, increased admission derived fibrinogen remained a significant predictor of increased hazard of MACE at two years [HR 2.22 (1.03– 4.77)]. In the same model, BNP [HR 0.95 (0.82–1.08)] and CRP [HR 1.22 (1.01–1.47)] were less robust prognosticators. In patients admitted with an acute myocardial infarction who undergo PCI with stent placement, admission derived fibrinogen levels, a widely available analyte, are more strongly predictive of future major adverse cardiac events than BNP and CRP.
Treatment of Pernicious Anemia with Congo Red
Journal: Journal of Clinical Investigation (1936)

ment of Pernicious Anemia with Congo Red." Page 456, 15th line of abstract, for sentence " One case of pernicious anemia at a low blood level failed to improve on the daily administration of a small amount of liver extract."read " One case of pernicious anemia at a low blood level failed to improve on a daily adminis- tration of Congo red although a full remission followed the administration of a small amount of liver extract."
TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
Authors: Scott T. Tagawa, Daniel Peter Petrylak, Petros Grivas, Neeraj Agarwal, Cora N. Sternberg, Peggy Siemon-Hryczyk, Trishna Goswam, Yohann Loriot
Journal: Journal of Clinical Oncology (2019)

TPS495 Background: Patients (pts) with unresectable locally advanced or metastatic urothelial cancer (mUC) who progress after platinum-based chemotherapy and checkpoint inhibitor (CPI) therapy and pts ineligible for platinum-based chemotherapy who progress after CPI have limited treatment options and poor outcomes. Trop-2 is an epithelial cell surface antigen that is overexpressed in UC. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate that targets Trop-2 and delivers the active metabolite (SN38) of the topoisomerase I inhibitor irinotecan to tumor cells. In a phase 1/2 single-arm trial, pts with advanced cancers received SG 10 mg/kg intravenously on days 1 and 8 of a 21-day cycle; preliminary results in the cohort of 41 evaluable pts with mUC and a median of 3 (range 1–6) prior therapies showed an objective response rate (ORR) of 34%. Adverse events (AE) were mostly low grade, including diarrhea (63%), nausea (56%), and fatigue (49%). Neutropenia (all grades) occurred in 49% of pts (≥ grade 3/4, 39%; treatment-related serious AE of febrile neutropenia, 5%). Median overall survival was 16.1 months, and median progression-free survival was 7.1 months. These results warrant further investigation in a dedicated phase 2 trial. Methods: TROPHY-U-01 is a single-arm, open-label, global phase 2 trial evaluating the antitumor activity and safety of SG in 140 pts with advanced UC. The primary cohort (progression after platinum chemotherapy and CPI) will enroll 100 pts in a Simon 2-stage design with &gt; 90% power accounting for dropouts to exclude the null hypothesis or ORR &lt; 12%, while a second cohort (40 pts) will comprise cisplatin-ineligible pts who received prior CPI. The primary objective is ORR per RECIST 1.1, assessed by central review. Secondary objectives include response duration, PFS, OS, and safety/tolerability. Enrollment began in August 2018. Clinical trial information: NCT03547973.
Propranolol and hyperthyroidism. Reversal of upper motor neuron signs
Authors: M. P. Rothberg
Journal: JAMA (1974)

UPPER motor neuron signs of weakness, spasticity, and hyperreflexia are infrequent complications of hyperthyroidism.<sup>1</sup>This article describes a patient with these signs, which improved dramatically and promptly after institution of propranolol hydrochloride therapy. <h3>Report of a Case</h3> A 53-year-old man was hospitalized because of a seven-week history of progressive weakness of both lower extremities, resulting in inability to walk. He denied bowel or bladder difficulties, back pain, dysphagia, or dysarthria. In 1970 he had been treated with 8 millicuries of sodium iodide I 131 for hyperthyroidism, but did not return for follow-up evaluation. Physical examination revealed a thin and cooperative man who was somewhat confused and unable to provide a clear history. The pulse rate was 120 beats per minute and regular, blood pressure was 110/70 mm Hg, and the skin was warm and moist. The thyroid gland was not palpable. He had stigmata of thyroid eye disease consisting
DOCTORS FOR BRITAIN
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
Authors: J. Baselga, A. Manikhas, J. Cortés, A. Llombart, L. Roman, V.F. Semiglazov, M. Byakhov, D. Lokanatha, S. Forenza, R.H. Goldfarb, J. Matera, N. Azarnia, C.A. Hudis, M. Rozencweig
Journal: Annals of Oncology (2019)

Ann Oncol 2014; 25: 592–598 (doi: 10.1093/annonc/mdt543) In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB is the consultant and on the advisory board for Roche and Novartis. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancerAnnals of OncologyVol. 25Issue 3PreviewNonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet®) in combination with trastuzumabHerceptin® (Hoffmann-La Roche) has shown promising activity and cardiac safety. We conducted a randomized phase III trial of first-line NPLD plus trastuzumab and paclitaxel (Pharmachemie B.V.) (MTP) versus trastuzumab plus paclitaxel (TP) in patients with human epidermal growth factor 2 receptor (HER2)-positive metastatic breast cancer. Full-Text PDF Open Archive
AMA offers nutrition clerkships
Journal: JAMA (1980)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Morphological and Behavioral Markers of Environmentally Induced Retardation of Brain Development: An Animal Model
Authors: Joseph Altman
Journal: Environmental Health Perspectives (1987)

In most neurotoxicological studies morphological assessment focuses on pathological effects, like degenerative changes in neuronal perikarya, axonopathy, demyelination, and glial and endothelial cell reactions. Similarly, the assessment of physiological and behavioral effects center on evident neurological symptoms, like EEG and EMG abnormalities, resting and intention tremor, abnormal gait, and abnormal reflexes. This paper reviews briefly another central nervous system target of harmful environmental agents, which results in behavioral abnormalities without any qualitatively evident neuropathology. This is called microneuronal hypoplasia, a retardation of brain development characterized by a quantitative reduction in the normal population of late-generated, short-axoned neurons in specific brain regions. Correlated descriptive and experimental neurogenetic studies in the rat have established that all the cerebellar granule cells and a very high proportion of hippocampal granule cells are produced postnatally, and that focal, low-dose X-irradiation either of the cerebellum or of the hippocampus after birth selectively interferes with the acquisition of the full complement of granule cells (microneuronal hypoplasia). Subsequent behavioral investigations showed that cerebellar microneuronal hypoplasia results in profound hyperactivity without motor abnormalities, while hippocampal microneuronal hypoplasia results in hyperactivity, as well as attentional and learning deficits. There is much indirect clinical evidence that various harmful environmental agents affecting the pregnant mother and/or the infant lead to such childhood disorders as hyperactivity and attentional and learning disorders. As the developing human brain is more mature at birth than the rat brain, the risk for microneuronal hypoplasia and consequent behavioral disorders may be highest at late stages of fetal development, in prematurely born and small-for-weight infants, and during the early stages of infant development. Recent technological advances in brain imaging techniques make it possible to test this hypothesis and to assess the possible relationship between the degree of retarded brain development and ensuing behavioral disorders.
The case for using industrial quality management science in health care organizations
Authors: G. Laffel
Journal: JAMA (1989)

In an effort to provide health care of optimal quality, providers traditionally assess or measure performance and then assure that it conforms to standards. In cases where performance fails to conform, providers attempt to modify or improve physician behavior. The analytic scope of this traditional paradigm may not be broad enough to allow modern health care organizations to provide optimal care. At a theoretical and practical level, many conceptual limitations inherent in the traditional approach are addressed in modern industrial quality science. A fundamental principle of industrial quality control is the recognition, analysis, and elimination of variation. Based on rigorous analysis of variation in outcomes and processes, industrial quality experts have developed principles and techniques for quality improvement. Health care organizations may well make important advances in the quality of care and service through the application of these principles and techniques. (<i>JAMA</i>. 1989;262:2869-2873)
Abstract 14: Diet Quality and Cardiovascular Disease Risk in Postmenopausal Women With Type 2 Diabetes: the Women’s Health Initiative
Authors: Kristin M Hirahatake, Andrew Odegaard, Nathan Wong, Shaista Malik, Luohua Jiang, James Shikany, Charles Eaton, Matthew Allison, Lisa Martin, Lorena Garcia, Oleg Zaslavsky
Journal: Circulation (2017)

Introduction: Both type 2 diabetes (T2D) and cardiovascular disease (CVD) are known to be influenced by dietary intake, however there is little evidence from large and well characterized cohort studies regarding the relationship between popular dietary patterns and CVD risk in populations with T2D. Understanding how common diet scores associate with CVD risk may provide better nutrition recommendations, education, and targeted interventions in the population with T2D. Hypothesis: We hypothesize that high diet quality as represented by higher scores on four different a priori diet indices is associated with a lower risk of developing CVD in postmenopausal women with T2D. Methods: We analyzed data of 6031 postmenopausal women with type 2 diabetes from the Women’s Health Initiative (WHI) cohort with no history of CVD at baseline. Dietary intake was assessed by a validated WHI food frequency questionnaire. Diet scores for four different diet patterns were calculated: Mediterranean (aMed), Dietary Approaches to Stop Hypertension (DASH), Paleolithic diet, and American Diabetes Association dietary recommendations (ADA). Multivariate Cox proportional hazards regression was used to estimate the hazard ratio of incident coronary heart disease (CHD) and stroke during study follow up for each dietary pattern score, adjusting for demographic, lifestyle and clinical measures. Results: Over 21 years of follow up 11.2% (675/6031) of women developed CHD and 6.7% (408/6031) had a stroke. There was a strong, monotonic inverse association between higher aMed, DASH, and ADA diet scores and risk of incident CHD and stroke; and no association between the Paleolithic dietary pattern score and CHD or stroke (Table 1). Conclusions: There are multiple dietary avenues to lower CVD risk in a population with T2D via the aMed, DASH, and ADA diets; whereas there was no evidence the Paleolithic diet score is associated with CVD risk in a population with T2D.